GLPwatch
Mounjaro for Heart failure (HFpEF)
tirzepatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCMounjaro (tirzepatide) is not FDA-approved for heart failure with preserved ejection fraction (HFpEF), and its use for this condition is off-label/investigational. A study is examining tirzepatide in patients with HFpEF, but no efficacy or approval details are provided.
AI summary of the sources below.
| Drug | Mounjaro (tirzepatide) |
|---|---|
| Condition | Heart failure (HFpEF) |
| Approval status | Investigational / off-label |
| Research papers | 27 |
Mounjaro is not FDA-approved for heart failure (hfpef); the research below reflects investigational or off-label study only.
Research on tirzepatide for heart failure (hfpef) (27)
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy.
- Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial.
- Tirzepatide attenuates lipopolysaccharide-induced left ventricular remodeling and dysfunction by inhibiting the TLR4/NF-kB/NLRP3 pathway.
- Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity.
- Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction.
- Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial.
- Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT Trial.
- Tirzepatide alleviates doxorubicin-induced cardiotoxicity via inhibiting HRD1-mediated Nrf2 ubiquitination.
- Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis.
- Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis.
- Comparative effectiveness of semaglutide <i>versus</i> liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis.
- Call to action for drug interactions between tirzepatide and heart failure guideline-directed medical therapy.
- Effectiveness of tirzepatide in patients with HFpEF using a target trial emulation retrospective cohort study.
- Tirzepatide for the treatment of heart failure in Type 2 diabetes mellitus: (SUR)PASS, or not?
- Tirzepatide, a dual GIP/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide.
- Real-world efficacy of tirzepatide in patients with heart failure without diabetes.
- Semaglutide vs tirzepatide in patients with obesity and HFpEF: a report from a global federated research network.
- Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management.
- GLP-1RAs and tirzepatide may reduce heart failure risk in obese but not in non-obese patients with cardiovascular or renal disease: A systematic review and meta-analysis.
- Reaching the SUMMIT? Benefits and potential risks associated with the use of tirzepatide in heart failure with preserved ejection fraction.
- Comparative Outcomes of Tirzepatide and Semaglutide in Patients With Heart Failure With Preserved Ejection Fraction and Type 2 Diabetes.
- Effect of Tirzepatide on Heart Failure in Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Meta-Analysis.
- Efficacy and safety of Tirzepatide in patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis.
- Semaglutide and Tirzepatide for the Treatment of Obesity and Weight-Related Comorbidities: A Narrative Review.